Bakker Juliet Tammenoms - Net Worth and Insider Trading

Bakker Juliet Tammenoms Net Worth

The estimated net worth of Bakker Juliet Tammenoms is at least $343 Million dollars as of 2024-05-15. Bakker Juliet Tammenoms is the 10% Owner of Aimmune Therapeutics Inc and owns about 6,029,785 shares of Aimmune Therapeutics Inc (AIMT) stock worth over $208 Million. Bakker Juliet Tammenoms is the Director of Axonics Inc and owns about 1,959,859 shares of Axonics Inc (AXNX) stock worth over $132 Million. Bakker Juliet Tammenoms is also the Director of RxSight Inc and owns about 31,388 shares of RxSight Inc (RXST) stock worth over $2 Million. Besides these, Bakker Juliet Tammenoms also holds Eargo Inc (EAR) . Details can be seen in Bakker Juliet Tammenoms's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bakker Juliet Tammenoms has not made any transactions after 2024-02-14 and currently still holds the listed stock(s).

Transaction Summary of Bakker Juliet Tammenoms

Bakker Juliet Tammenoms Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bakker Juliet Tammenoms owns 20 companies in total, including Eargo Inc (EAR) , Axonics Inc (AXNX) , and Molecular Templates Inc (MTEM) among others .

Click here to see the complete history of Bakker Juliet Tammenoms’s form 4 insider trades.

Insider Ownership Summary of Bakker Juliet Tammenoms

Ticker	Comapny	Transaction Date	Type of Owner
EAR	Eargo Inc	2020-10-20	director & 10 percent owner
AXNX	Axonics Inc	2020-09-18	director & 10 percent owner
MTEM	Molecular Templates Inc	2019-11-25	10 percent owner
		2020-07-23	10 percent owner
		2019-11-08	10 percent owner
		2020-06-11	10 percent owner
		2019-11-07	director
		2019-11-22	10 percent owner
		2018-06-27	10 percent owner
		2018-06-20	10 percent owner
		2018-02-22	10 percent owner
		2015-05-06	10 percent owner
		2017-07-19	10 percent owner
		2008-03-25	director & 10 percent owner
		2014-10-07	10 percent owner
		2024-02-14	director
		2021-07-19	10 percent owner
		2021-05-06	10 percent owner
		2022-02-10	10 percent owner
		2023-11-02	10 percent owner

Bakker Juliet Tammenoms Latest Holdings Summary

Bakker Juliet Tammenoms currently owns a total of 4 stocks. Among these stocks, Bakker Juliet Tammenoms owns 6,029,785 shares of Aimmune Therapeutics Inc (AIMT) as of February 22, 2018, with a value of $208 Million and a weighting of 60.69%. Bakker Juliet Tammenoms owns 1,959,859 shares of Axonics Inc (AXNX) as of September 18, 2020, with a value of $132 Million and a weighting of 38.6%. Bakker Juliet Tammenoms also owns 31,388 shares of RxSight Inc (RXST) as of February 14, 2024, with a value of $2 Million and a weighting of 0.56%. The other 1 stocks Eargo Inc (EAR) have a combined weighting of 0.15% among all his current holdings.

Latest Holdings of Bakker Juliet Tammenoms

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AIMT	Aimmune Therapeutics Inc	2018-02-22	6,029,785	34.49	207,967,285
AXNX	Axonics Inc	2020-09-18	1,959,859	67.49	132,270,884
RXST	RxSight Inc	2024-02-14	31,388	61.63	1,934,442
EAR	Eargo Inc	2020-10-20	195,935	2.57	503,553

Holding Weightings of Bakker Juliet Tammenoms

Bakker Juliet Tammenoms Form 4 Trading Tracker

According to the SEC Form 4 filings, Bakker Juliet Tammenoms has made a total of 0 transactions in Aimmune Therapeutics Inc (AIMT) over the past 5 years. The most-recent trade in Aimmune Therapeutics Inc is the acquisition of 9,375 shares on February 22, 2018, which cost Bakker Juliet Tammenoms around $300,000.

According to the SEC Form 4 filings, Bakker Juliet Tammenoms has made a total of 2 transactions in Axonics Inc (AXNX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Axonics Inc is the sale of 9,167 shares on September 18, 2020, which brought Bakker Juliet Tammenoms around $391,156.

According to the SEC Form 4 filings, Bakker Juliet Tammenoms has made a total of 8 transactions in RxSight Inc (RXST) over the past 5 years, including 3 buys and 5 sells. The most-recent trade in RxSight Inc is the acquisition of 8,000 shares on February 14, 2024, which cost Bakker Juliet Tammenoms around $406,640.

More details on Bakker Juliet Tammenoms's insider transactions can be found in the Insider Trading History of Bakker Juliet Tammenoms table.

Insider Trading History of Bakker Juliet Tammenoms

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bakker Juliet Tammenoms Trading Performance

GuruFocus tracks the stock performance after each of Bakker Juliet Tammenoms's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bakker Juliet Tammenoms is 20.58%. GuruFocus also compares Bakker Juliet Tammenoms's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bakker Juliet Tammenoms within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bakker Juliet Tammenoms's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bakker Juliet Tammenoms

Average Return

Average return per transaction

Outperforming Transactions

2 out of 5 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-2.11
Relative Return to S&P 500(%)	-2.5

Bakker Juliet Tammenoms Ownership Network

Ownership Network List of Bakker Juliet Tammenoms

No Data

Ownership Network Relation of Bakker Juliet Tammenoms

Bakker Juliet Tammenoms Owned Company Details

What does Eargo Inc do?

Who are the key executives at Eargo Inc?

Bakker Juliet Tammenoms is the director & 10 percent owner of Eargo Inc. Other key executives at Eargo Inc include Chief Accounting Officer Mark Thorpe , Chief Operating Officer William Brownie , and Chief Financial Officer Adam Laponis .

Eargo Inc (EAR) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Eargo Inc (EAR). Other recent insider transactions involving Eargo Inc (EAR) include a net sale of 2,012 shares made by William Brownie , a net sale of 725 shares made by Adam Laponis , and a net sale of 92 shares made by Mark Thorpe .

In summary, during the past 3 months, insiders sold 0 shares of Eargo Inc (EAR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,799 shares of Eargo Inc (EAR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,799 shares.

Eargo Inc (EAR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eargo Inc Insider Transactions

No Available Data

What does Axonics Inc do?

Who are the key executives at Axonics Inc?

Bakker Juliet Tammenoms is the director & 10 percent owner of Axonics Inc. Other key executives at Axonics Inc include Chief Financial Officer Kari Leigh Keese , Chief Medical Officer Karen Noblett , and director & Chief Executive Officer Raymond W Cohen .

Axonics Inc (AXNX) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Axonics Inc (AXNX). Other recent insider transactions involving Axonics Inc (AXNX) include a net sale of 66,432 shares made by Danny L. Dearen , a net sale of 78,838 shares made by Ford Alfred J Jr , and a net sale of 39,921 shares made by Karen Noblett .

In summary, during the past 3 months, insiders sold 0 shares of Axonics Inc (AXNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 397,082 shares of Axonics Inc (AXNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 397,082 shares.

Axonics Inc (AXNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axonics Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 250,000 shares, with a net purchase of 250,000 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Inozyme Pharma Inc do?

Who are the key executives at Inozyme Pharma Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and 10 percent owner Longitude Capital Partners Iii, Llc .

Inozyme Pharma Inc (INZY) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,833,697 shares made by Robert Lorne Hopfner , a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , and a net sale of 7,523 shares made by Douglas A Treco .

In summary, during the past 3 months, insiders sold 7,523 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 7,523 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,667,030 shares were bought by its insiders, resulting in a net purchase of 2,659,507 shares.

Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inozyme Pharma Inc Insider Transactions

No Available Data

What does 89bio Inc do?

Who are the key executives at 89bio Inc?

Bakker Juliet Tammenoms is the 10 percent owner of 89bio Inc. Other key executives at 89bio Inc include director & Chief Executive Officer Rohan Palekar , director & 10 percent owner Ra Capital Healthcare Fund Lp , and See Remarks Quoc Le-nguyen .

89bio Inc (ETNB) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in 89bio Inc (ETNB). Other recent insider transactions involving 89bio Inc (ETNB) include a net sale of 27,280 shares made by Ryan Martins , a net sale of 87,195 shares made by Rohan Palekar , and a net purchase of 3,811,538 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 57,195 shares of 89bio Inc (ETNB) in total and bought 1,350,000 shares, with a net purchase of 1,292,805 shares. During the past 18 months, 146,908 shares of 89bio Inc (ETNB) were sold and 3,899,326 shares were bought by its insiders, resulting in a net purchase of 3,752,418 shares.

89bio Inc (ETNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

89bio Inc Insider Transactions

No Available Data

What does Vaxcyte Inc do?

Who are the key executives at Vaxcyte Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Vaxcyte Inc. Other key executives at Vaxcyte Inc include SVP & Gen Counsel & Corp Sec Mikhail Eydelman , Chief Operating Officer Jim Wassil , and director & President & CEO Grant Pickering .

Vaxcyte Inc (PCVX) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Vaxcyte Inc (PCVX). Other recent insider transactions involving Vaxcyte Inc (PCVX) include a net sale of 125,936 shares made by Grant Pickering , a net sale of 70,000 shares made by Andrew Guggenhime , and a net sale of 21,000 shares made by Jim Wassil .

In summary, during the past 3 months, insiders sold 80,244 shares of Vaxcyte Inc (PCVX) in total and bought 0 shares, with a net sale of 80,244 shares. During the past 18 months, 273,265 shares of Vaxcyte Inc (PCVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 273,265 shares.

Vaxcyte Inc (PCVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vaxcyte Inc Insider Transactions

No Available Data

What does Venus Concept Inc do?

Who are the key executives at Venus Concept Inc?

Bakker Juliet Tammenoms is the director of Venus Concept Inc. Other key executives at Venus Concept Inc include President Global Sales Ross Portaro , 10 percent owner Michael Willingham Masters , and 10 percent owner Marlin Master Fund Offshore Ii, Lp .

Venus Concept Inc (VERO) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Venus Concept Inc (VERO). Other recent insider transactions involving Venus Concept Inc (VERO) include a net sale of 257,143 shares made by Anthony Natale , a net purchase of 1,250,000 shares made by Silva Rajiv De , and a net purchase of 250,000 shares made by Stanley Tyler Hollmig .

In summary, during the past 3 months, insiders sold 0 shares of Venus Concept Inc (VERO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,143 shares of Venus Concept Inc (VERO) were sold and 120,667 shares were bought by its insiders, resulting in a net purchase of 103,524 shares.

Venus Concept Inc (VERO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Venus Concept Inc Insider Transactions

No Available Data

What does Sierra Oncology Inc do?

Who are the key executives at Sierra Oncology Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .

Sierra Oncology Inc (SRRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sierra Oncology Inc Insider Transactions

No Available Data

What does Tricida Inc do?

Who are the key executives at Tricida Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Tricida Inc. Other key executives at Tricida Inc include director & 10 percent owner Orbimed Advisors Llc , director & 10 percent owner David P Bonita , and 10 percent owner Venrock Healthcare Capital Partners Ii, L.p. .

Tricida Inc (TCDAQ) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Tricida Inc (TCDAQ). Other recent insider transactions involving Tricida Inc (TCDAQ) include a net sale of 159,463 shares made by Robert J Alpern , a net sale of 10,280,947 shares made by Orbimed Advisors Llc , and a net sale of 10,280,947 shares made by David P Bonita .

In summary, during the past 3 months, insiders sold 0 shares of Tricida Inc (TCDAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 20,721,357 shares of Tricida Inc (TCDAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 20,721,357 shares.

Tricida Inc (TCDAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tricida Inc Insider Transactions

No Available Data

What does Aptinyx Inc do?

Who are the key executives at Aptinyx Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Aptinyx Inc. Other key executives at Aptinyx Inc include director & CEO and President Norbert G Riedel , CFO and CBO Ashish Khanna , and 10 percent owner Bain Capital Life Sciences Investors, Llc .

Aptinyx Inc (APTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aptinyx Inc (APTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptinyx Inc (APTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aptinyx Inc (APTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aptinyx Inc Insider Transactions

No Available Data

What does Aimmune Therapeutics Inc do?

Who are the key executives at Aimmune Therapeutics Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .

Aimmune Therapeutics Inc (AIMT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aimmune Therapeutics Inc Insider Transactions

No Available Data

What does Collegium Pharmaceutical Inc do?

Who are the key executives at Collegium Pharmaceutical Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP & Chief Commercial Officer Scott Dreyer , director & President and CEO Joseph Ciaffoni , and EVP and General Counsel Shirley R. Kuhlmann .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 362,915 shares made by Joseph Ciaffoni , a net sale of 298,612 shares made by Michael Thomas Heffernan , and a net sale of 65,395 shares made by Shirley R. Kuhlmann .

In summary, during the past 3 months, insiders sold 10,000 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 778,316 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 778,316 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

What does Kala Bio Inc do?

Who are the key executives at Kala Bio Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Kala Bio Inc. Other key executives at Kala Bio Inc include CHIEF BUSINESS OFFICER Darius Kharabi , Chief Financial Officer Mary Reumuth , and director & Chief Executive Officer Mark T Iwicki .

Kala Bio Inc (KALA) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Kala Bio Inc (KALA). Other recent insider transactions involving Kala Bio Inc (KALA) include a net sale of 4,737 shares made by Mark T Iwicki , a net sale of 1,690 shares made by Romulus K Brazzell , and a net sale of 1,467 shares made by Todd Bazemore .

In summary, during the past 3 months, insiders sold 0 shares of Kala Bio Inc (KALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,853 shares of Kala Bio Inc (KALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,853 shares.

Kala Bio Inc (KALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kala Bio Inc Insider Transactions

No Available Data

What does Corcept Therapeutics Inc do?

Who are the key executives at Corcept Therapeutics Inc?

Bakker Juliet Tammenoms is the director & 10 percent owner of Corcept Therapeutics Inc. Other key executives at Corcept Therapeutics Inc include Chief Accounting Officer Joseph Douglas Lyon , See Remarks Sean Maduck , and Chief Development Officer William Guyer .

Corcept Therapeutics Inc (CORT) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Corcept Therapeutics Inc (CORT). Other recent insider transactions involving Corcept Therapeutics Inc (CORT) include a net sale of 60,000 shares made by Joseph Douglas Lyon , a net sale of 175,625 shares made by Sean Maduck , and a net sale of 24,200 shares made by Swisher Daniel N Jr .

In summary, during the past 3 months, insiders sold 106,600 shares of Corcept Therapeutics Inc (CORT) in total and bought 0 shares, with a net sale of 106,600 shares. During the past 18 months, 400,274 shares of Corcept Therapeutics Inc (CORT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 400,274 shares.

Corcept Therapeutics Inc (CORT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corcept Therapeutics Inc Insider Transactions

No Available Data

What does Esperion Therapeutics Inc do?

Who are the key executives at Esperion Therapeutics Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Esperion Therapeutics Inc. Other key executives at Esperion Therapeutics Inc include Chief Commercial Officer Eric Warren , Chief Operating Officer Sheldon L. Koenig , and Chief Medical Officer Joanne M. Foody .

Esperion Therapeutics Inc (ESPR) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Esperion Therapeutics Inc (ESPR). Other recent insider transactions involving Esperion Therapeutics Inc (ESPR) include a net sale of 7,644 shares made by Eric Warren , a net sale of 9,821 shares made by Joanne M. Foody , and a net purchase of 7,560 shares made by Sheldon L. Koenig .

In summary, during the past 3 months, insiders sold 0 shares of Esperion Therapeutics Inc (ESPR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,542 shares of Esperion Therapeutics Inc (ESPR) were sold and 59,611 shares were bought by its insiders, resulting in a net purchase of 22,069 shares.

Esperion Therapeutics Inc (ESPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Esperion Therapeutics Inc Insider Transactions

No Available Data

What does RxSight Inc do?

Who are the key executives at RxSight Inc?

Bakker Juliet Tammenoms is the director of RxSight Inc. Other key executives at RxSight Inc include director & See Remarks Kurtz Ronald M Md , Chief Financial Officer Shelley B Thunen , and Chief Operating Officer Ilya Goldshleger .

RxSight Inc (RXST) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made 7 insider transaction in RxSight Inc (RXST) with a net sale of 588,606. Other recent insider transactions involving RxSight Inc (RXST) include a net sale of 83,431 shares made by Ilya Goldshleger , a net sale of 50,000 shares made by Eric Weinberg , and a net sale of 116,772 shares made by Shelley B Thunen .

In summary, during the past 3 months, insiders sold 75,000 shares of RxSight Inc (RXST) in total and bought 0 shares, with a net sale of 75,000 shares. During the past 18 months, 1,554,918 shares of RxSight Inc (RXST) were sold and 488,000 shares were bought by its insiders, resulting in a net sale of 1,066,918 shares.

RxSight Inc (RXST)'s detailed insider trading history can be found in Insider Trading Tracker table.

RxSight Inc Insider Transactions

No Available Data

What does Rapid Micro Biosystems Inc do?

Who are the key executives at Rapid Micro Biosystems Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Rapid Micro Biosystems Inc. Other key executives at Rapid Micro Biosystems Inc include Chief Financial Officer Sean M Wirtjes , director & President and CEO Spignesi Robert G. Jr. , and 10 percent owner Kennedy Lewis Capital Partners Master Fund Ii Lp .

Rapid Micro Biosystems Inc (RPID) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Rapid Micro Biosystems Inc (RPID). Other recent insider transactions involving Rapid Micro Biosystems Inc (RPID) include a net purchase of 74,000 shares made by Spignesi Robert G. Jr. , and a net purchase of 10,000 shares made by Sean M Wirtjes .

In summary, during the past 3 months, insiders sold 0 shares of Rapid Micro Biosystems Inc (RPID) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rapid Micro Biosystems Inc (RPID) were sold and 84,000 shares were bought by its insiders, resulting in a net purchase of 84,000 shares.

Rapid Micro Biosystems Inc (RPID)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rapid Micro Biosystems Inc Insider Transactions

No Available Data

What does Talaris Therapeutics Inc do?

Who are the key executives at Talaris Therapeutics Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Talaris Therapeutics Inc. Other key executives at Talaris Therapeutics Inc include Interim CFO Ryan F. Robinson , Chief Technology Officer Susan Dana Jones , and Chief Regulatory Officer Kevin Bruce Johnson .

Talaris Therapeutics Inc (TALS) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Talaris Therapeutics Inc (TALS). Other recent insider transactions involving Talaris Therapeutics Inc (TALS) include a net sale of 505,845 shares made by Suzanne Ildstad ,

In summary, during the past 3 months, insiders sold 0 shares of Talaris Therapeutics Inc (TALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 50,585 shares of Talaris Therapeutics Inc (TALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 50,585 shares.

Talaris Therapeutics Inc (TALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talaris Therapeutics Inc Insider Transactions

No Available Data

What does Vera Therapeutics Inc do?

Who are the key executives at Vera Therapeutics Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Vera Therapeutics Inc. Other key executives at Vera Therapeutics Inc include SVP & Finance & Chief Acct Offcr Joseph R Young , Chief Financial Officer Sean Grant , and director & 10 percent owner Maha Katabi .

Vera Therapeutics Inc (VERA) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Vera Therapeutics Inc (VERA). Other recent insider transactions involving Vera Therapeutics Inc (VERA) include a net purchase of 441,721 shares made by Beth C Seidenberg , a net sale of 27,196 shares made by Joanne Curley , and a net sale of 99,192 shares made by Sean Grant .

In summary, during the past 3 months, insiders sold 958,650 shares of Vera Therapeutics Inc (VERA) in total and bought 0 shares, with a net sale of 958,650 shares. During the past 18 months, 2,042,546 shares of Vera Therapeutics Inc (VERA) were sold and 4,784,797 shares were bought by its insiders, resulting in a net purchase of 2,742,251 shares.

Vera Therapeutics Inc (VERA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vera Therapeutics Inc Insider Transactions

No Available Data

What does Lexeo Therapeutics Inc do?

Who are the key executives at Lexeo Therapeutics Inc?

Bakker Juliet Tammenoms is the 10 percent owner of Lexeo Therapeutics Inc. Other key executives at Lexeo Therapeutics Inc include director & Chief Executive Officer Richard Nolan Townsend , 10 percent owner Lundbeckfond Invest A/s , and 10 percent owner Omega Fund Vi Gp, L.p. .

Lexeo Therapeutics Inc (LXEO) Insider Trades Summary

Over the past 18 months, Bakker Juliet Tammenoms made no insider transaction in Lexeo Therapeutics Inc (LXEO). Other recent insider transactions involving Lexeo Therapeutics Inc (LXEO) include a net purchase of 454,545 shares made by Omega Fund Vi Gp, L.p. , a net purchase of 454,545 shares made by Longitude Capital Partners Iv, Llc , and a net purchase of 227,272 shares made by Lundbeckfond Invest A/s .

In summary, during the past 3 months, insiders sold 5,000 shares of Lexeo Therapeutics Inc (LXEO) in total and bought 0 shares, with a net sale of 5,000 shares. During the past 18 months, 5,000 shares of Lexeo Therapeutics Inc (LXEO) were sold and 1,136,362 shares were bought by its insiders, resulting in a net purchase of 1,131,362 shares.

Lexeo Therapeutics Inc (LXEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lexeo Therapeutics Inc Insider Transactions

No Available Data

Bakker Juliet Tammenoms Mailing Address

Above is the net worth, insider trading, and ownership report for Bakker Juliet Tammenoms. You might contact Bakker Juliet Tammenoms via mailing address: Longitude Capital Management Co., Llc, 800 El Camino Real, Suite 220, Menlo Park Ca 94025.

Discussions on Bakker Juliet Tammenoms

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.